The Generation of hiPSC Models for CNS-relevant Cell-Based Assays
Sponsored by: Ncardia
- Drug Discovery
- Neurological Diseases
- Neuronal Models
Date: 22 October
Days to go: 21
Time: 3PM London/10AM New York
The development of physiologically relevant models for neurological diseases remains a challenge with an unfilled gap in translatable human-based platforms. The use of recombinant cell lines or animal models does not always fully recapitulate the complexity of human disease. Primary human tissues, on the other spectrum, are typically difficult to obtain and frequently unavailable in large quantities and at sufficiently reliable levels of reproducibility. Furthermore, a limited menu of physiologically relevant and predictive cell-based assays is a key obstacle to recapitulate human neuropathology, as for example in seizure.
With the emergence of human induced pluripotent stem cell (hiPSC) technology, it is now possible to design and manufacture CNS cell models such as neurons, astrocytes and microglia that are critical players in multiple disease pathogenesis. The application of in vitro predictive seizurogenic assays, such as MEA technology platforms, have been shown to be essential in monitoring and characterizing neuronal spontaneous activity in diverse neuronal models and to modulate neuronal networks that are crucial to understand seizure patterns and participating pathways.
During this webinar we discuss the advantages, challenges and solutions of generating and implementing hiPSC- derived neuronal models in drug discovery, disease modelling and assay development.
To gain an insight and to better understand the challenges and benefits of hiPSC-derived neuronal models, then do register for this webinar presented by Ncardia’s Head of Product Management and a leading CNS cell & disease model development scientist.
Steven Dublin, PhD,
Head of Product Management
Steven Dublin obtained his PhD in Chemistry from Emory University in 2007 and subsequently worked as a post-doctoral researcher in Biomedical Engineering at the Georgia Institute of Technology. With more than a decade of experience developing and commercializing products at biotech and large Pharma companies, he is now the Head of Product Management at Ncardia.
Isabel Onofre, PhD,
Cell Development Scientist
Isabel is a cell & disease model development scientist at Ncardia. She obtained her PhD in Pharmaceutical Biotechnology in 2016, and subsequently worked as a post-doctoral researcher at Sanford Burnham Prebys Medical Discovery Institute. Isabel has extensive experience in modelling human neurodegenerative diseases in iPSC-derived neurons and the development of predictive seizurogenic assays on MEA.
Key Learning Objectives
- Understand the benefits and challenges of hiPSC-derived neuronal models
- Gain insight into the generation and optimization of an iPSC cell model and culture system
- See the application of a predictive seizure assay using Microelectrode Array (MEA) technology and hiPSC-derived neurons
- Chief Technology Officer
- Head of Screening
- Head of Assay Development
- Program Director
- Head of Cellular Technologies
- Senior Scientist
- Chief Scientific Officer
- Scientific Director
- Director Program Management
- Principal Scientist
- Head of Drug Discovery